Row bottom right peak Shape Decorative svg added to bottom

Life Sciences Investment
Banking & Strategic Advisory

Partnering with biotech, pharmaceutical, and healthcare companies to unlock value through licensing, capital raising, M&A, and advisory services.

Independent. Experienced. Globally connected.

Row bottom right peak Shape Decorative svg added to top

EVOLUTION Life Science Partners

Is a dedicated investment banking and strategic advisory firm focused exclusively on life sciences and healthcare companies. Founded to provide unbiased, independent advice, we partner with companies across their lifecycle, from early-stage innovation to commercial-stage growth.

Our team brings decades of combined experience, having worked together for over 15 years and participated in more than 100 transactions globally.

Learn More About Us

What we do

We help life sciences companies navigate critical inflection points with tailored, strategic guidance:

Strategic Transactions
Licensing, partnering, mergers & acquisitions, and fairness opinions to maximize deal outcomes.

Capital Markets Advisory
Equity and debt financings, valuation analysis, and investor engagement.

Pre-Transaction Strategy
Roadmaps to value creation, identifying milestones and positioning companies for successful transactions.

These services are designed to support companies at every stage from pre-clinical to commercial.

Who we serve

We work with companies across the life sciences ecosystem, including:

• Biotechnology

• Pharmaceutical

• Diagnostics

• Medical Devices

• Life Science Services

Our clients range from emerging innovators to established global organizations, typically engaging at the CEO, CFO, and board level

Row bottom right peak Shape Decorative svg added to top

Our Track Record

Consumer
2025
Management Buy-out
Non-Disclosed
Strategic Advisor
CNS
2024
Strategic Consulting Assignment
N/A
Strategic Advisor
Consumer
2023
Acquisition by Pharmavite
$425,000,000
Financial Co-adviser
Hematology
2022
Co-Promotion Partnership for the US
$35,000,000
Strategic Advisor
Oncology
2022
Out-license to SeaGen
$700,000,000
Strategic Consultant
Hematology
2021
Capital Raise
$35,000,000
Financial Advisor
CRO / R&D
2021
Acquisition by West-Atlantic Partners
Non Disclosed
Strategic Advisor
Oncology
2020
Out-license of regional rights for Apealea to Inceptua Group
Not Disclosed
Strategic Advisor
Oncology
2020
Investment by BDI Col Ltd.
$12,000,000
Placement Agent
Diagnostics
2020
Acquisition by BioNano Genomics
$10,740,000
Strategic Advisor
View all Transactions